Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.48 |
| ▸ | PTK6 | Q13882 | 2/20 | 0.40 |
| ▸ | VDR | P11473 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | BRAF | P15056 | 3/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | VNN1 | O95497 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13429337 | 0.89 | GAA (0.45) | KDM4EPTK6VDRALDH1A1KMT2A | |
| SCHEMBL3205934 | 0.79 | LMNA (0.45) | KDM4EALDH1A1HSD17B10HPGDMAPK1 | |
| SCHEMBL3214639 | 0.78 | SMN1; SMN2 (0.49) | KDM4EPTK6ALDH1A1MAPTKMT2A | |
| SCHEMBL3202341 | 0.77 | HPGD (0.47) | KDM4EALDH1A1MAPTKMT2AHSD17B10 | |
| SCHEMBL3220447 | 0.77 | PTK6 (0.41) | KDM4EPTK6ALDH1A1KMT2ABRAF | |
| SCHEMBL3222698 | 0.75 | ALDH1A1 (0.43) | KDM4EALDH1A1KMT2AHSD17B10HPGD | |
| SCHEMBL7937526 | 0.74 | ALDH1A1 (0.53) | KDM4EALDH1A1MAPTKMT2AHSD17B10 | |
| SCHEMBL13429262 | 0.73 | F2 (0.46) | KDM4EPTK6KMT2ABRAF | |
| SCHEMBL13429381 | 0.72 | MEN1 (0.44) | PTK6ALDH1A1MAPTKMT2ABRAF | |
| SCHEMBL13429115 | 0.71 | HPGD (0.51) | KDM4EALDH1A1MAPTKMT2AHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100068204-A1 | 4-ARYLOXYQUINOLIN-2(1H)-ONES AS MTOR KINASE AND PI3 KINASE INHIBITORS, FOR USE AS ANTI-CANCER AGENTS | WYETH (US) | 2010-03-18 | — | — | US | disclosed |
| US-20100068204-A1 | 4-ARYLOXYQUINOLIN-2(1H)-ONES AS MTOR KINASE AND PI3 KINASE INHIBITORS, FOR USE AS ANTI-CANCER AGENTS | WYETH (US) | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100068204-A1 | 4-ARYLOXYQUINOLIN-2(1H)-ONES AS MTOR KINASE AND PI3 KINASE INHIBITORS, FOR USE AS ANTI-CANCER AGENTS | MTOR, RICTOR, PIK3CA | KDM4E 728/4885PTK6 146/4885VDR 1826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.